filovirda
caus
sporad
outbreak
sever
hemorrhag
fever
case
fatal
rate
high
posit
charg
antisens
phosphorodiamid
morpholino
oligom
pmoplu
target
viral
nucleoprotein
gene
evalu
potenti
therapeut
intervent
marv
infect
follow
delay
treatment
h
postinfect
pi
nonhuman
primat
lethal
challeng
model
total
cynomolgu
macaqu
divid
group
infect
plaqu
form
unit
marv
subcutan
administ
bolu
infus
daili
day
mgkg
bodi
weight
surviv
primari
endpoint
studi
none
salin
group
surviv
infect
monkey
surviv
treatment
initi
h
postinfect
pi
antisens
treatment
also
reduc
serum
viremia
inflammatori
cytokin
treatment
group
compar
vehicl
control
antibodi
immun
respons
viru
preserv
tissu
viral
antigen
clear
treat
anim
data
show
protect
nhp
otherwis
lethal
marv
infect
treatment
initi
h
pi
marburg
viru
marv
filoviru
close
relat
ebola
viru
similarli
caus
hemorrhag
fever
human
marv
endem
throughout
part
tropic
africa
sever
outbreak
marburg
viru
diseas
mvd
occur
involv
hundr
plo
neglect
tropic
diseas
marburg
viru
marv
member
famili
filovirida
highli
virul
caus
hemorrhag
fever
human
nonhuman
primat
human
marburg
viru
diseas
mvd
typic
begin
high
fever
accompani
sever
headach
chill
myalgia
malais
mani
patient
follow
abdomin
pain
sever
nausea
vomit
wateri
diarrhea
day
patient
develop
form
hemorrhag
manifest
mucos
bleed
bloodi
diarrhea
hematemesi
ecchymosi
later
stage
diseas
manifest
multiorgan
failur
shock
coma
acut
liver
failur
concomit
increas
liverassoci
enzym
common
diseas
manifest
case
fatal
rate
approach
death
typic
occur
day
follow
onset
symptom
marv
outbreak
often
occur
subsaharan
africa
pose
public
health
threat
african
popul
travel
region
threat
exemplifi
occurr
two
larg
outbreak
democrat
republ
congo
angola
togeth
result
greater
case
death
marv
close
relat
ebola
viru
possibl
larger
outbreak
similar
current
ebola
viru
diseas
outbreak
west
africa
marv
genom
negativesens
singl
strand
rna
approxim
kb
encod
seven
gene
includ
np
nucleoprotein
polymeras
cofactor
matrix
protein
gp
glycoprotein
transcript
activ
secondari
matrix
protein
rnadepend
rna
polymeras
l
protein
gene
product
repres
potenti
target
develop
therapeut
agent
current
licens
vaccin
antivir
therapi
marv
infect
although
sever
approach
activ
pursu
postexposur
therapeut
intervent
daddariodicaprio
et
al
show
first
complet
postexposur
protect
nonhuman
primat
marv
infect
use
liveattenu
recombin
vesicular
stomat
viru
vaccin
vector
express
marv
gp
howev
construct
given
min
viral
challeng
safeti
efficaci
therapeut
modal
human
subject
remain
unproven
postexposur
administr
recombin
nematod
anticoagul
protein
strategi
design
mitig
coagulopathi
seen
sever
marv
infect
fail
provid
substant
protect
infect
monkey
recent
studi
use
liposom
formul
small
interf
rna
sirna
target
np
gene
marv
guinea
pig
nonhuman
primat
model
promis
addit
studi
demonstr
import
marv
np
gene
viral
assembl
viral
rna
synthesi
highlight
critic
role
np
gene
play
life
cycl
marv
antisens
oligom
synthet
molecul
design
interfer
translat
gene
product
steric
block
mrna
result
inhibit
gene
express
design
prevent
viral
replic
bind
np
mrna
sequencespecif
manner
thu
steric
block
translat
phosphorodiamid
morpholino
oligom
pmo
uncharg
antisens
compound
compos
moieti
morpholino
base
link
phosphorodiamid
linkag
oppos
ribos
base
rna
link
methylen
phosphorodiamid
pmo
attract
antivir
agent
due
metabol
stabil
bioavail
pmo
peptideconjug
pmo
ppmo
shown
inhibit
replic
ebola
viru
coxsackieviru
influenza
viru
alphavirus
vesivirus
dengu
viru
sever
acut
respiratori
syndromeassoci
coronaviru
previou
report
introduc
new
class
positivelycharg
pmo
pmoplu
contain
piperazin
linkag
within
molecular
backbon
contain
limit
number
posit
charg
posit
charg
may
enhanc
cellular
penetr
avid
neg
charg
rna
target
sequenc
viru
previous
show
administr
pmoplu
combin
therapi
contain
antisens
agent
target
np
marv
provid
protect
cynomolgu
macaqu
given
min
infect
subsequ
show
singl
agent
design
target
np
marv
effect
combin
therapi
present
studi
evalu
efficaci
alon
cynomolgu
macaqu
delay
timetotreat
studi
pmoplu
administ
h
follow
infect
marv
anim
research
us
armi
medic
research
institut
infecti
diseas
usamriid
conduct
institut
anim
care
use
committe
iacuc
approv
protocol
complianc
anim
welfar
act
ph
polici
feder
statut
regul
relat
anim
experi
involv
anim
facil
research
conduct
accredit
associ
assess
accredit
laboratori
anim
care
intern
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
thirti
male
femal
healthi
cynomolgu
macaqu
macaca
fasciculari
obtain
primat
product
inc
immokale
fl
anim
hous
individu
stainless
steel
cage
enrich
toy
provid
fruit
monkey
chow
biscuit
water
ad
libitum
anim
sedat
blood
collect
procedur
use
ketamin
mgml
acepromazin
mgml
mlkg
administ
intramuscularli
four
day
viral
challeng
blood
sampl
collect
determin
baselin
valu
anim
serum
chemistri
valu
hematolog
coagul
paramet
macaqu
random
five
group
six
anim
includ
least
one
femal
group
anim
challeng
plaqu
form
unit
pfu
marv
musok
subcutan
inject
administ
daili
bolu
iv
inject
dose
mgkg
begin
approxim
h
viru
challeng
infectioncontrol
group
receiv
iv
salin
nacl
accord
regimen
begin
h
challeng
tabl
summar
anim
group
treatment
regimen
marvinfect
anim
handl
maximum
contain
biosafeti
level
laboratori
usamriid
frederick
maryland
viral
challeng
macaqu
monitor
close
sign
clinic
diseas
euthanasia
perform
accord
prespecifi
criteria
blood
sampl
collect
anim
day
pi
macaqu
surviv
day
consid
surviv
viral
challeng
vero
cell
obtain
american
type
cultur
collect
atcc
maintain
dulbecco
modifi
eagl
medium
life
technolog
usa
supplement
fetal
bovin
serum
fb
life
technolog
usa
marburg
viru
marburg
viru
h
sapienstc
use
studi
origin
isol
serum
infect
patient
propag
total
six
passag
vero
cell
posit
charg
pmo
pmoplu
contain
piperazin
linkag
within
molecular
backbon
design
sequenc
homolog
overlap
aug
translat
start
site
marv
np
gene
pmoplu
design
sequenc
repres
posit
charg
piperazin
moieti
synthes
sarepta
therapeut
cambridg
previous
describ
serum
sampl
serial
dilut
eagl
essenti
minim
medium
ad
duplic
well
vero
cell
monolay
plate
incub
secondari
agaros
overlay
contain
neutral
red
appli
well
h
aid
plaqu
visual
lower
limit
quantif
assay
pfuml
tissu
collect
viral
load
assess
collect
store
analysi
includ
adren
gland
femor
bone
marrow
brain
heart
kidney
liver
lung
lymph
node
spleen
testesovari
prior
use
assay
tissu
homogen
cell
cultur
medium
ratio
tissu
ml
medium
use
handheld
homogen
dispos
rotor
homogen
subject
plaqu
assay
describ
serum
quantit
rtpcr
total
rna
extract
trizol
lstreat
serum
sampl
use
magmax
blood
rna
isol
kit
ambion
purifi
rna
sampl
store
assay
qrtpcr
assay
perform
sampl
triplic
use
abi
prism
sequenc
detect
system
rna
ultrasensetm
onestep
kit
invitrogen
taqman
probe
abi
accord
manufactur
instruct
marv
musokespecif
primer
probe
taagacagtgcacmgb
use
reaction
least
six
serial
dilut
quantifi
marv
genom
rna
use
gener
standard
curv
quantif
genom
copi
per
volum
serum
calcul
cyclethreshold
valu
obtain
sampl
compar
use
standardcurv
equat
lower
limit
quantif
analysi
x
genom
equivalentsml
serum
total
rna
trizol
lstreat
plasma
use
viral
genom
sequenc
quantiti
viral
rna
present
plasma
sampl
assess
qrtpcr
sampl
submit
sequenc
analysi
x
copiesml
limit
viral
rna
avail
sequenc
analysi
particular
sampl
prioriti
place
determin
sequenc
viral
genom
base
code
transcript
region
target
prioriti
region
nucleotid
marv
genom
genbank
access
approxim
nucleotid
region
blood
chemistri
profil
determin
use
vitro
chemistri
system
ortho
clinic
diagnost
coagul
analysi
perform
use
sysmex
siemen
serum
sampl
analyz
determin
circul
cytokinechemokin
concentr
use
meso
scale
discoveri
platform
meso
scale
diagnost
msd
rockvil
md
accord
manufactur
instruct
human
proinflammatori
kit
gmcsf
human
ultrasensit
kit
human
chemokin
kit
eotaxin
tarc
mdc
purchas
msd
reagent
provid
msd
kit
assay
perform
accord
manufactur
recommend
procedur
assess
develop
virusspecif
humor
immun
respons
analysi
serum
sampl
subject
limit
dilut
elisa
evalu
titer
antimarv
gp
immunoglobulin
g
igg
igm
recombin
marv
gp
lot
obtain
nation
cancer
institut
frederick
md
serum
sampl
ad
assay
duplic
use
dilut
seri
begin
dilut
viru
end
dilut
antihuman
horseradish
peroxidas
conjug
antibodi
use
detect
sure
blue
tm
tmb
solut
kpl
inc
use
substrat
anim
euthan
intravenouslyadminist
pentobarbit
full
necropsi
conduct
carcass
monkey
sampl
follow
organ
collect
anim
determin
tissu
viral
titer
plaqu
assay
axillari
lymph
node
inguin
lymph
node
mesenter
lymph
node
liver
spleen
adren
gland
kidney
gonad
heart
lung
femor
bone
marrow
brain
complet
set
tissu
sampl
also
collect
monkey
analysi
routin
histolog
immunohistochemistri
ihc
tissu
collect
histopatholog
ihc
immersionfix
neutral
buffer
formalin
minimum
day
remov
contain
tissu
sampl
trim
routin
process
embed
paraffin
section
paraffinembed
tissu
thick
cut
histolog
histolog
slide
deparaffin
stain
hematoxylin
eosin
replic
set
slide
produc
routin
histolog
made
ihc
immunoperoxidas
assay
use
cocktail
two
mous
monoclon
antibodi
marv
primari
antibodi
complet
unstain
slide
tissu
section
slide
counterstain
hematoxylin
anim
randomli
assign
treatment
group
stratifi
sex
balanc
bodi
weight
due
safeti
consider
studi
personnel
experiment
blind
use
singleblind
condit
salinecontrol
h
pi
treatment
group
studi
data
analyz
computer
statist
program
sa
version
mean
time
death
evalu
use
student
ttest
kaplanmei
surviv
analysi
use
calcul
surviv
curv
well
median
mean
surviv
time
result
surviv
curv
compar
logrank
mantelcox
test
use
prism
graphpad
softwar
graphpad
inc
lajolla
ca
sampl
size
permit
physiolog
respons
assess
use
student
ttest
anova
total
cynomolgu
macaqu
challeng
lethal
dose
marv
initi
treatment
occur
h
viral
infect
infect
control
administr
salin
one
salinetr
monkey
die
day
anim
control
group
succumb
day
pi
fig
develop
characterist
mvd
sign
fever
petechi
rash
contrast
five
six
monkey
h
pi
treatment
group
surviv
monkey
six
six
h
pi
treatment
group
surviv
fig
although
death
one
anim
die
h
pi
treatment
group
attribut
complic
associ
anesthesia
administr
mild
sign
mvd
monkey
mortal
treat
treatment
failur
includ
surviv
statist
differ
surviv
pbsand
group
highli
statist
signific
p
differ
surviv
group
receiv
treatment
statist
indistinguish
signific
differ
observ
anim
bodi
temperatur
weight
cours
studi
serum
viral
rna
first
detect
day
salin
control
anim
approxim
anim
treatment
cohort
anim
viremia
peak
day
pi
fig
fig
data
consist
viral
genom
copi
number
determin
qrtpcr
fig
fig
peak
viremia
day
pi
mean
viral
load
monkey
reduc
approxim
time
salinetr
anim
fig
survivor
viral
load
measur
plaqu
assay
qrtpcr
serum
began
decreas
day
pi
decreas
undetect
level
day
remain
undetect
end
studi
day
salinetr
macaqu
viru
detect
nearli
tissu
analyz
fig
highest
viral
titer
gener
present
liver
gonad
spleen
rang
x
x
pfug
tissu
substanti
variabl
tissuespecif
viral
load
individu
anim
group
fig
viru
detect
multipl
tissu
two
three
anim
succumb
viru
detect
tissu
obtain
anim
surviv
except
one
anim
h
pi
treatment
group
anim
test
posit
viru
tissu
includ
bone
marrow
brain
kidney
inguin
mesenter
lymph
node
howev
viral
titer
tissu
gener
low
rang
x
x
pfug
tissu
viral
antigen
detect
immunohistochemistri
low
titer
infecti
viru
tissu
undetect
level
remain
survivor
tissu
indic
resolut
viru
infect
popul
genom
analysi
bloodborn
marv
reveal
viru
one
anim
h
pi
treatment
group
acquir
mutat
region
flank
bind
site
mutat
appear
result
drugresist
phenotyp
nucleotid
chang
toler
anim
surviv
infect
marv
evid
mutat
seen
viru
anim
studi
liver
damag
subsequ
increas
liver
enzym
common
diseas
manifest
vhf
includ
caus
marv
mani
anim
exhibit
mark
increas
serum
aspart
aminotransferas
ast
day
elev
resolv
day
survivor
day
ast
significantli
increas
pbstreat
control
compar
anim
h
p
p
pi
group
fig
similar
ast
serum
alanin
aminotransferas
alt
level
increas
surviv
anim
increas
serum
alp
ggt
taken
togeth
data
suggest
hepatocellular
damag
infect
anim
partial
complet
resolut
survivor
day
blood
urea
nitrogen
bun
significantli
increas
p
four
surviv
salinetr
control
compar
anim
group
fig
increas
bun
indic
decreas
kidney
function
may
caus
decreas
blood
flow
kidney
due
dehydr
andor
shock
statist
signific
p
increas
neutrophil
macaqu
salin
treatment
group
compar
h
h
treatment
group
suggest
viralinduc
neutrophilia
prevent
treat
anim
fig
viralinduc
coagulopathi
common
featur
mvd
human
nonhuman
primat
consist
decreas
platelet
count
observ
anim
group
fig
decreas
associ
increas
mpv
suggest
adapt
bone
marrow
respons
treat
survivor
fig
marvinduc
coagulopathi
evidenc
prolong
multipl
coagul
paramet
includ
tt
fig
pt
fig
fig
immun
respons
marvspecif
igm
detect
anim
day
pi
point
found
low
titer
anim
day
pi
marvspecif
igm
detect
surviv
anim
gener
reach
maximum
titer
rang
fig
gradual
reduct
igm
observ
anim
day
pi
marvspecif
igg
first
detect
day
pi
anim
fig
antisens
treatment
marburg
viru
day
pi
marvspecif
igg
detect
surviv
anim
titer
gener
increas
day
day
pi
plateau
thereaft
end
studi
titer
rang
elev
level
sever
proinflammatori
chemokin
includ
eotaxin
observ
late
infect
peak
day
anim
treatment
group
howev
peak
level
eotaxin
fig
lower
anim
salinetr
anim
also
show
increas
mdc
tarc
prior
death
averag
higher
observ
treat
anim
fig
result
postmortem
anatom
patholog
analys
indic
pbstreat
control
anim
develop
fatal
marv
infect
gross
histolog
lesion
immunohistochemistri
find
typic
previous
seen
cynomolgu
macaqu
experiment
infect
marv
organ
consist
sever
affect
liver
spleen
liver
lesion
consist
multipl
foci
hepatocellular
degener
necrosi
accompani
vari
degre
acut
inflamm
fig
ihc
demonstr
abund
marv
antigen
present
within
lesion
fig
spleen
moder
mark
lymphoid
deplet
white
pulp
usual
accompani
lysi
lymphocyt
deposit
fibrin
adjac
red
pulp
fig
larg
amount
viral
antigen
present
within
histiocyt
cell
red
white
pulp
well
extracellular
fibrin
fig
three
monkey
fail
surviv
end
studi
one
anim
pi
treatment
group
die
anesthesia
day
experi
marvinduc
lesion
organ
mild
compar
control
caus
death
attribut
anesthet
complic
rather
marv
infect
two
treat
monkey
fail
surviv
one
h
pi
group
one
h
pi
group
lesion
indic
marv
infect
caus
death
howev
case
microscop
lesion
andor
ihc
result
typic
present
control
anim
suggest
treatment
affect
viral
infect
contrast
control
anim
liver
treat
monkey
surviv
end
studi
minim
virusinduc
damag
marv
antigen
detect
ihc
fig
rather
lymphoid
deplet
occur
control
hyperplasia
lymphoid
tissu
spleen
lymphoid
organ
survivor
fig
like
respons
system
antigen
stimul
viral
challeng
ihc
reveal
marv
antigen
spleen
survivor
fig
seventeen
survivor
male
eight
anim
h
pi
treatment
group
foci
mild
moder
testicular
inflamm
viral
antigen
lesion
one
monkey
pi
treatment
group
immunoposit
testicular
lesion
also
viral
antigen
within
acellular
debri
crypt
palatin
tonsil
one
femal
survivor
monkey
h
pi
treatment
group
faint
stain
viral
antigen
macrophag
within
foci
inflamm
thyroid
gland
marv
antigen
detect
tissu
monkey
surviv
end
studi
mvd
human
usual
character
high
fever
anorexia
diarrhea
petechi
rash
variou
hemorrhag
manifest
clinic
sign
also
reproduc
experimentallyinfect
cynomolgu
macaqu
recent
report
demonstr
postexposur
treatment
protect
rhesu
monkey
marvangola
strain
treatment
delay
day
previous
shown
highli
effect
provid
surviv
benefit
cynomolgu
macaqu
infect
musok
strain
marv
howev
pmoplu
therapi
experiment
studi
began
day
infect
contrast
treatment
regimen
infect
human
would
usual
need
initi
longer
post
infect
time
period
henc
import
determin
potenti
benefit
initi
treatment
significantli
delay
infect
thu
primari
object
studi
determin
surviv
benefit
provid
initi
administ
four
day
infect
musok
strain
marv
util
cynomolgu
macaqu
anim
model
control
anim
studi
succumb
marv
infect
wherea
anim
treat
surviv
differ
surviv
rate
control
group
treat
anim
highli
signific
furthermor
differ
surviv
group
receiv
treatment
differ
time
pi
statist
distinguish
two
three
treat
anim
h
group
h
group
succumb
infect
slow
mount
igg
immun
respons
titer
respect
howev
low
igg
titer
adequ
provid
reliabl
marker
surviv
sever
survivor
low
igg
titer
day
pi
notabl
relationship
magnitud
durat
marvspecif
igg
respons
time
dose
macaqu
surviv
overal
result
studi
indic
administ
iv
per
day
total
day
protect
cynomolgu
macaqu
marv
even
treatment
initi
late
h
viral
infect
treat
macaqu
surviv
viral
challeng
ihc
reveal
presenc
marv
antigen
organ
nine
anim
one
monkey
faint
stain
viral
antigen
macrophag
within
foci
inflamm
thyroid
gland
although
possibl
indic
persist
viral
infect
thyroid
like
macrophag
contain
viral
antigen
due
phagocytosi
cellular
debri
contain
viral
antigen
similarli
anoth
anim
viral
antigen
acellular
debri
within
tonsillar
crypt
probabl
reflect
persist
isol
viral
antigen
rather
presenc
intact
viabl
viral
particl
howev
eight
male
monkey
testicular
lesion
posit
viral
antigen
foci
testicular
inflamm
might
indic
macaqu
persist
marv
infect
time
death
consist
find
human
die
marv
origin
outbreak
autopsi
reveal
larg
necrot
lesion
testicl
furthermor
man
surviv
marv
infect
outbreak
believ
infect
wife
via
sexual
contact
week
clinic
recoveri
viabl
marv
subsequ
recov
semin
sampl
late
week
discharg
hospit
possibl
vener
transmiss
may
confin
marv
household
contact
ebola
patient
kikwit
outbreak
presum
infect
sexual
intercours
four
five
convalesc
patient
examin
semin
fluid
sampl
pcr
posit
ebola
viru
given
ongo
larg
ebola
viru
epidem
west
africa
sexual
transmiss
viru
concern
interestingli
although
eight
survivor
male
macaqu
studi
marv
antigen
testicular
lesion
none
tissu
yield
viabl
viru
plaqu
assay
suggest
treatment
suppress
viral
replic
anim
test
addit
research
need
done
clarifi
potenti
viral
persist
testi
studi
show
antisens
compound
highli
effect
marv
infect
demonstr
efficaci
compound
administ
four
day
infect
marv
cynomolgu
macaqu
anim
model
note
infect
anim
first
becam
pcr
posit
day
first
show
clinic
sign
diseas
day
post
infect
administr
result
mark
improv
surviv
amelior
laboratori
patholog
manifest
marv
diseas
current
ebola
viru
outbreak
west
africa
remind
us
need
identifi
effect
antivir
product
advanc
emerg
situat
area
filoviru
therapeut
develop
deserv
studi
particularli
defin
limit
treatment
success
initi
furthermor
recent
shown
safe
welltoler
human
develop
effect
marv
therapeut
